Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study

Table 1 Baseline characteristics of patients receiving intravenous iron dextran stratified by darbepoetin exposure

	Darbepoetin	No darbepoetin	P value
	N = 94	N = 14	P value
Demographics
Age	69.51 ± 15.90	67.79 ± 17.26	0.7088 (T)
Race, n (White, Black, Asian, Hispanic)	45/47/1/1	13/1/0/0	0.0181 (F)
Gender, n (Female/Male)	58/36	11/3	0.2202 (C)
Laboratory
Baseline platelets (1000/mm³)	304.53 ± 106.97	313.71 ± 124.87	0.7699 (T)
Hemoglobin (g/dL)	9.98 ± 1.22	11.44 ± 1.43	<0.0001 (T)
Transferrin saturation (%)	13.07 ± 6.26	12.71 ± 4.41	0.8361 (T)
Ferritin (ng/mL)	43.07 ± 36.05	33.50 ± 23.10	0.3379 (T)
CKD stage
Stage 1	1 (1%)	0 (0%)	0.4453 (C)
Stage 2	6 (6%)	0 (0%)
Stage 3	40 (43%)	9 (64%)
Stage 4	38 (40%)	5 (36%)
Stage 5	9 (10%)	0 (0%)

Demographics are reported as frequencies except for age which is reported as mean ± standard deviation. Laboratory parameters are reported as mean ± standard deviation. Chronic kidney disease (CKD) stages are reported as frequencies with percentages in parenthesis. (T) = Two-sided T-Test, (C) = Chi-Square Test, (F) = Fisher Exact Test.

ISSN: 1471-2369